{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:07Z","timestamp":1787315227697,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2024.1428726","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:40:00Z","timestamp":1726706400000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Opinion: can we bust the fear of symptomatic intracerebral hemorrhage due to tPA?"],"prefix":"10.3389","volume":"15","author":[{"given":"Adalia H.","family":"Jun-O'Connell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","article-title":"Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"48","author":"Yaghi","year":"2017","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e12646","DOI":"10.1002\/emp2.12646","article-title":"Tissue plasminogen activator and patients with acute ischemic stroke: the litigation landscape","volume":"3","author":"Ganti","year":"2022","journal-title":"J Am Coll Emerg Physicians Open."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.09.23296783","article-title":"Persistent inequities in intravenous thrombolysis for acute ischemic stroke in the united states: results from the nationwide inpatient sample","author":"Sun","year":"2023","journal-title":"medRxiv."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(08)61339-2","article-title":"Thrombolysis with alteplase 3-45 h after acute ischaemic stroke (SITS-ISTR): an observational study","volume":"372","author":"Wahlgren","year":"2008","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1161\/STROKEAHA.119.025080","article-title":"Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials","volume":"50","author":"Burgos","year":"2019","journal-title":"Stroke"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1468-1331.1995.tb00074.x","article-title":"European Cooperative Acute Stroke Study (ECASS): (rt-PA-Thrombolysis in acute stroke) study design and progress report","volume":"1","author":"Boysen","year":"1995","journal-title":"Eur J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clineuro.2015.08.031","article-title":"United States trends in thrombolysis for older adults with acute ischemic stroke","volume":"139","author":"George","year":"2015","journal-title":"Clin Neurol Neurosurg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1756286421997368","DOI":"10.1177\/1756286421997368","article-title":"Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence","volume":"14","author":"Tsivgoulis","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"599908","DOI":"10.3389\/fneur.2020.599908","article-title":"Intracranial hemorrhage after reperfusion therapies in acute ischemic stroke patients","volume":"11","author":"Ma\u00efer","year":"2020","journal-title":"Front Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1161\/STROKEAHA.107.487009","article-title":"Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm","volume":"38","author":"Saver","year":"2007","journal-title":"Stroke."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1001\/jama.2013.6959","article-title":"Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke","volume":"309","author":"Saver","year":"2013","journal-title":"Jama."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1161\/STROKEAHA.108.543561","article-title":"Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 45-hour window","volume":"40","author":"Saver","year":"2009","journal-title":"Stroke."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","volume":"379","author":"IST-3","year":"2012","journal-title":"The Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"Cd000213","DOI":"10.1161\/STROKEAHA.114.007024","article-title":"Thrombolysis for acute ischaemic stroke","volume":"2014","author":"Wardlaw","year":"2014","journal-title":"Cochr Datab Syst Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199906103402302","article-title":"Effects of tissue plasminogen activator for acute ischemic stroke at one year. National institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study group","volume":"340","author":"Kwiatkowski","year":"1999","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1001\/jama.2020.5697","article-title":"Association between thrombolytic door-to-needle time and 1-year mortality and readmission in patients with acute ischemic stroke","volume":"323","author":"Man","year":"2020","journal-title":"Jama."},{"key":"B26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1474-4422(13)70130-3","article-title":"Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial","volume":"12","author":"IST-3","year":"2013","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e88652","DOI":"10.1371\/journal.pone.0088652","article-title":"Predictors of critical care needs after IV thrombolysis for acute ischemic stroke","volume":"9","author":"Faigle","year":"2014","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/STROKEAHA.118.021398","article-title":"Shorter intensive care unit stays? The majority of post-intravenous tPA (tissue-type plasminogen activator) symptomatic hemorrhages occur within 12 hours of treatment","volume":"49","author":"Chang","year":"2018","journal-title":"Stroke."},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/14737175.2017.1347039","article-title":"Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries","volume":"17","author":"Tsivgoulis","year":"2017","journal-title":"Expert Rev Neurother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/archneur.61.7.1066","article-title":"Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke","volume":"61","author":"Saver","year":"2004","journal-title":"Arch Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(16)30076-X","article-title":"Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis","volume":"15","author":"Whiteley","year":"2016","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000339675","article-title":"Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions","volume":"34","author":"Seet","year":"2012","journal-title":"Cerebrovasc Dis."},{"key":"B33","unstructured":"AssociationAM\n          Specifications Manual for Joint Commission National Quality Measures (v2022B1): Measure Set: Comprehensive Stroke (CSTK)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"703258","DOI":"10.3389\/fneur.2021.703258","article-title":"Hemorrhagic transformation after ischemic stroke: mechanisms and management","volume":"12","author":"Hong","year":"2021","journal-title":"Front Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/jcm11051162","article-title":"Hemorrhagic transformation in acute ischemic stroke: a quantitative systematic review","volume":"11","author":"Honig","year":"2022","journal-title":"J Clin Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1161\/01.STR.30.11.2280","article-title":"Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort Stroke","volume":"30","author":"Fiorelli","year":"1999","journal-title":"Stroke."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0142381","DOI":"10.1371\/journal.pone.0142381","article-title":"Thrombolytic-related asymptomatic hemorrhagic transformation does not deteriorate clinical outcome: data from TIMS in China","volume":"10","author":"Jia","year":"2015","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13311-023-01377-1","article-title":"Hemorrhagic conversion of acute ischemic stroke","volume":"20","author":"Zubair","year":"2023","journal-title":"Neurotherapeutics."},{"key":"B39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1586\/14737175.7.7.783","article-title":"Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies","volume":"7","author":"K\u00fclkens","year":"2007","journal-title":"Expert Rev Neurother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e002193","DOI":"10.1161\/JAHA.115.002193","article-title":"Association of acute and chronic hyperglycemia with acute ischemic stroke outcomes post-thrombolysis: findings from get with the guidelines-stroke","volume":"4","author":"Masrur","year":"2015","journal-title":"J Am Heart Assoc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamaneurol.2024.1312","article-title":"Contemporary prestroke dual antiplatelet use and symptomatic intracerebral hemorrhage risk after thrombolysis","volume":"81","author":"Peng","year":"2024","journal-title":"JAMA Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(10)70165-4","article-title":"Implementation and outcome of thrombolysis with alteplase 3-4","volume":"9","author":"Ahmed","year":"2010","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1428726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:40:03Z","timestamp":1726706403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1428726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":43,"alternative-id":["10.3389\/fneur.2024.1428726"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1428726","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1428726"}}